Aims This study aimed to evaluate the efficacy and safety of regdanvimab, an anti‐SARS‐
COV‐2 monoclonal antibody approved by the European Medicines Agency in November …

Background: This study aims to evaluate the real-world effectiveness of regdanvimab on
clinical outcomes in patients with mild to moderate coronavirus disease 2019 (COVID-19) …

Regdanvimab has decreased the time to clinical recovery from coronavirus disease 2019
(COVID-19) and lowered the rate of oxygen therapy according to the results from Phase 2 …

Background Regdanvimab has decreased the time to clinical recovery from coronavirus
disease 2019 (COVID-19) and lowered the rate of oxygen therapy according to the results …

Background Regdanvimab is a monoclonal antibody with activity against SARS-CoV-2. A
Phase 2/3 study with two parts is currently ongoing and data up to Day 28 of Part 1 is …

Background Real-world clinical data concerning regdanvimab, a monoclonal antibody
treatment for patients with mild-to-moderate coronavirus disease 2019 (COVID-19), are …

We read with great interest that biologic medications might be a promising therapeutic
option in COVID-19. 1 Neutralizing monoclonal antibodies such as regdanvimab can reduce …

Introduction Regdanvimab, a neutralising monoclonal antibody (mAb) against severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), received approval for the treatment of …

ABSTRACT Background In a Phase III study, regdanvimab (CT-P59) reduced the risk of
hospitalization or death versus placebo in patients with mild-to-moderate coronavirus …

Abstract Background Regdanvimab (CT-P59) is a neutralizing antibody authorized in
Republic of Korea for the treatment of adult patients with moderate or mild-COVID-19 who …